Peptide deformylase is a potential target for anti-Helicobacter pylori drugs: Reverse docking, enzymatic assay, and X-ray crystallography validation | |
Cai, Jianhua; Han, Cong; Hu, Tiancen; Zhang, Jian; Wu, Dalei; Wang, Fangdao; Liu, Yunqing; Ding, Jianping; Chen, Kaixian; Yue, Jianmin; Shen, Xu; Jiang, Hualiang | |
Corresponding Author | Shen, Xu(xshen@mail.shcnc.ac.cn) |
2006-09-01 | |
Source Publication | PROTEIN SCIENCE
![]() |
ISSN | 0961-8368 |
Volume | 15Issue:9Pages:2071-2081 |
Abstract | Colonization of human stomach by the bacterium Helicobacter pylori is a major causative factor for gastrointestinal illnesses and gastric cancer. However, the discovery of anti-H. pylori agents is a difficult task due to lack of mature protein targets. Therefore, identifying new molecular targets for developing new drugs against H. pylori is obviously necessary. In this study, the in-house potential drug target database (PDTD, http://www.dddc.ac.cn/tarfisdock/) was searched by the reverse docking approach using an active natural product (compound 1) discovered by anti-H. pylori screening as a probe. Homology search revealed that, among the 15 candidates discovered by reverse docking, only diaminopimelate decarboxylase (DC) and peptide deformylase (PDF) have homologous proteins in the genome of H. pylori. Enzymatic assay demonstrated compound 1 and its derivative compound 2 are the potent inhibitors against H. pylori PDF (HpPDF) with IC50 values of 10.8 and 1.25 mu M, respectively. X-ray crystal structures of HpPDF and the complexes of HpPDF with 1 and 2 were determined for the first time, indicating that these two inhibitors bind well with HpPDF binding pocket. All these results indicate that HpPDF is a potential target for screening new anti-H. pylori agents. In addition, compounds 1 and 2 were predicted to bind to HpPDF with relatively high selectivity, suggesting they can be used as leads for developing new anti-H. pylori agents. The results demonstrated that our strategy, reverse docking in conjunction with bioassay and structural biology, is effective and can be used as a complementary approach of functional genomics and chemical biology in target identification. |
Keyword | peptide deformylase protein crystallization reverse docking enzyme inhibitor Helicobacter pylori |
DOI | 10.1110/ps.062238406 |
Indexed By | SCI |
Language | 英语 |
WOS Research Area | Biochemistry & Molecular Biology |
WOS Subject | Biochemistry & Molecular Biology |
WOS ID | WOS:000240156400005 |
Publisher | COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT |
Citation statistics | |
Document Type | 期刊论文 |
Identifier | http://ir.imr.ac.cn/handle/321006/88120 |
Collection | 中国科学院金属研究所 |
Corresponding Author | Shen, Xu |
Affiliation | 1.Chinese Acad Sci, Shanghai Inst Biol Sci, Grad Sch Chinese Acad Sci, Shanghai Inst Mat Med,State Key Lab Drug Res,Drug, Shanghai 201203, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Prot, Shanghai 200031, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China 4.E China Univ Sci & Technol, Sch Pharm, Shanghai 200237, Peoples R China |
Recommended Citation GB/T 7714 | Cai, Jianhua,Han, Cong,Hu, Tiancen,et al. Peptide deformylase is a potential target for anti-Helicobacter pylori drugs: Reverse docking, enzymatic assay, and X-ray crystallography validation[J]. PROTEIN SCIENCE,2006,15(9):2071-2081. |
APA | Cai, Jianhua.,Han, Cong.,Hu, Tiancen.,Zhang, Jian.,Wu, Dalei.,...&Jiang, Hualiang.(2006).Peptide deformylase is a potential target for anti-Helicobacter pylori drugs: Reverse docking, enzymatic assay, and X-ray crystallography validation.PROTEIN SCIENCE,15(9),2071-2081. |
MLA | Cai, Jianhua,et al."Peptide deformylase is a potential target for anti-Helicobacter pylori drugs: Reverse docking, enzymatic assay, and X-ray crystallography validation".PROTEIN SCIENCE 15.9(2006):2071-2081. |
Files in This Item: | There are no files associated with this item. |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment